Annual SG&A
$57.28 M
+$9.26 M+19.29%
31 March 2024
Summary:
Immunovant annual selling, general & administrative expenses is currently $57.28 million, with the most recent change of +$9.26 million (+19.29%) on 31 March 2024. During the last 3 years, it has risen by +$17.77 million (+44.97%). IMVT annual SG&A is now at all-time high.IMVT Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$18.47 M
-$337.00 K-1.79%
30 September 2024
Summary:
Immunovant quarterly selling, general & administrative expenses is currently $18.47 million, with the most recent change of -$337.00 thousand (-1.79%) on 30 September 2024. Over the past year, it has increased by +$4.63 million (+33.45%). IMVT quarterly SG&A is now -1.79% below its all-time high of $18.81 million, reached on 30 June 2024.IMVT Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$3.51 B
-$323.01 M-10.13%
30 September 2024
Summary:
Immunovant TTM selling, general & administrative expenses is currently -$3.51 billion, with the most recent change of -$323.01 million (-10.13%) on 30 September 2024. Over the past year, it has dropped by -$3.56 billion (-6669.67%). IMVT TTM SG&A is now -719680.24% below its all-time high of $65.32 million, reached on 30 September 2024.IMVT TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMVT Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +19.3% | +33.5% | -6669.7% |
| 3 y3 years | +45.0% | +13.4% | -7365.6% |
| 5 y5 years | - | - | - |
IMVT Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +45.0% | -1.8% | +60.4% | -305.8% | at low |
| 5 y | 5 years | at high | +215.6% | -1.8% | +203.4% | <-9999.0% | at low |
| alltime | all time | at high | +215.6% | -1.8% | +203.4% | <-9999.0% | at low |
Immunovant Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $18.47 M(-1.8%) | $65.32 M(+7.6%) |
| June 2024 | - | $18.81 M(+26.9%) | $60.69 M(+5.9%) |
| Mar 2024 | $57.28 M(+19.3%) | $14.82 M(+12.2%) | $57.28 M(+4.4%) |
| Dec 2023 | - | $13.21 M(-4.5%) | $54.88 M(+2.7%) |
| Sept 2023 | - | $13.84 M(-10.1%) | $53.44 M(+3.8%) |
| June 2023 | - | $15.40 M(+24.0%) | $51.47 M(+7.2%) |
| Mar 2023 | $48.02 M(-11.4%) | $12.42 M(+5.5%) | $48.02 M(-5.5%) |
| Dec 2022 | - | $11.78 M(-0.8%) | $50.84 M(+0.5%) |
| Sept 2022 | - | $11.88 M(-0.6%) | $50.58 M(-8.0%) |
| June 2022 | - | $11.95 M(-21.6%) | $54.99 M(+1.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | $54.23 M(+37.2%) | $15.24 M(+32.4%) | $54.23 M(+10.0%) |
| Dec 2021 | - | $11.52 M(-29.3%) | $49.29 M(+2.0%) |
| Sept 2021 | - | $16.29 M(+45.7%) | $48.32 M(+17.8%) |
| June 2021 | - | $11.18 M(+8.5%) | $41.03 M(+3.8%) |
| Mar 2021 | $39.51 M(+117.7%) | $10.30 M(-2.3%) | $39.51 M(+11.2%) |
| Dec 2020 | - | $10.55 M(+17.2%) | $35.53 M(+14.4%) |
| Sept 2020 | - | $9.00 M(-6.9%) | $31.07 M(+40.8%) |
| June 2020 | - | $9.66 M(+53.0%) | $22.07 M(+77.9%) |
| Mar 2020 | $18.15 M | $6.32 M(+3.7%) | $12.40 M(+103.7%) |
| Dec 2019 | - | $6.09 M | $6.09 M |
FAQ
- What is Immunovant annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Immunovant?
- What is Immunovant annual SG&A year-on-year change?
- What is Immunovant quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Immunovant?
- What is Immunovant quarterly SG&A year-on-year change?
- What is Immunovant TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Immunovant?
- What is Immunovant TTM SG&A year-on-year change?
What is Immunovant annual selling, general & administrative expenses?
The current annual SG&A of IMVT is $57.28 M
What is the all time high annual SG&A for Immunovant?
Immunovant all-time high annual selling, general & administrative expenses is $57.28 M
What is Immunovant annual SG&A year-on-year change?
Over the past year, IMVT annual selling, general & administrative expenses has changed by +$9.26 M (+19.29%)
What is Immunovant quarterly selling, general & administrative expenses?
The current quarterly SG&A of IMVT is $18.47 M
What is the all time high quarterly SG&A for Immunovant?
Immunovant all-time high quarterly selling, general & administrative expenses is $18.81 M
What is Immunovant quarterly SG&A year-on-year change?
Over the past year, IMVT quarterly selling, general & administrative expenses has changed by +$4.63 M (+33.45%)
What is Immunovant TTM selling, general & administrative expenses?
The current TTM SG&A of IMVT is -$3.51 B
What is the all time high TTM SG&A for Immunovant?
Immunovant all-time high TTM selling, general & administrative expenses is $65.32 M
What is Immunovant TTM SG&A year-on-year change?
Over the past year, IMVT TTM selling, general & administrative expenses has changed by -$3.56 B (-6669.67%)